International Journal of Molecular Sciences

Journal Browser

► Journal Browser

Special Issue Editor

Dr. Ondrej Havranek

E-Mail Website
Guest Editor

BIOCEV and Department of Hematology - 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Interests: lymphoma; B-cell receptor signaling; PI3K/AKT signaling; tumor metabolism; circulating tumor DNA; epigenetics

Special Issue Information

Dear Colleagues,

B-cell lymphomas are the most frequent type of non-Hodgkin lymphomas (NHL), substantially contributing to cancer morbidity and mortality worldwide. They originate from B lymphocytes and represent about 85–90% of all NHL cases. They are a clinically and biologically heterogeneous group of malignant tumors, reflecting the complex biology of a normal B-cell lifecycle and function. In recent years, many studies reported unprecedented new insights into the mechanisms of lymphoma development and biology. This progress was greatly aided by complex lymphoma genomics studies, which laid the foundation for future in-depth lymphoma biology research.

The aim of this Special Issue is to report such novel insights into B-cell lymphoma biology related to tumor development, progression or treatment resistance. We would like to focus on studies ranging from the investigation of consequences of lymphoma-associated genetic alterations, the molecular characterization of lymphoma-specific cellular signaling or other key cellular processes, through to tumor microenvironmental interactions. Original, as well as review, articles are welcome. We look forward to receiving your contributions.

Dr. Ondrej Havranek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

B-cell lymphoma
non-Hodgkin lymphoma
tumor biology
cellular signaling
lymphoma-specific genetic alterations
tumor microenvironment

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

17 pages, 2148 KiB

Open AccessArticle

Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia

by Kristina Tomic Vujovic, Milena Ugrin, Natasa Tosic, Vojin Vukovic, Irena Marjanovic, Tatjana Kostic, Sanja Stankovic, Vladimir Otasevic, Sofija Sarac, Darko Antic, Sonja Pavlovic and Teodora Karan-Djurasevic

Int. J. Mol. Sci. 2024, 25(2), 922; https://doi.org/10.3390/ijms25020922 - 11 Jan 2024

Viewed by 914

Abstract

Dysregulated expression of the long non-coding RNA MALAT1 has been implicated in the pathogenesis and progression of a variety of cancers, including hematological malignancies, but it has been poorly investigated in chronic lymphocytic leukemia (CLL). In this study, the expression of MALAT1 was measured using a quantitative reverse-transcriptase polymerase chain reaction in the peripheral blood mononuclear cells of 114 unselected, newly diagnosed CLL patients in order to analyze its association with clinical, laboratory, and molecular patients’ characteristics at diagnosis, as well as its prognostic relevance. MALAT1 was found to be upregulated in CLL patients in comparison to healthy controls, and expression levels were not related to age, leukocyte, lymphocyte and platelet count, serum β2-microglobulin, and IGHV somatic hypermutational status. On the other hand, high MALAT1 expression was associated with several favorable prognostic markers (high hemoglobin, low serum lactate dehydrogenase, earlier clinical stages, CD38-negative status), but also with unfavorable cytogenetics. Furthermore, an association between high MALAT1 levels and longer time to first treatment and overall survival in IGHV-unmutated CLL subtype was observed. In summary, our results imply that high MALAT1 expression at diagnosis may be a predictor of better prognosis and point to MALAT1 expression profiling as a candidate biomarker potentially useful in clinical practice. Full article

(This article belongs to the Special Issue New Advances in B-cell Lymphoma Biology)

► Show Figures

Figure 1

Review

Jump to: Research

23 pages, 5410 KiB

Open AccessReview

B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells

by Anton Tkachenko, Kristyna Kupcova and Ondrej Havranek

Int. J. Mol. Sci. 2024, 25(1), 10; https://doi.org/10.3390/ijms25010010 - 19 Dec 2023

Cited by 4 | Viewed by 2082

Abstract

B-cell receptor (BCR) is a B cell hallmark surface complex regulating multiple cellular processes in normal as well as malignant B cells. Igα (CD79a)/Igβ (CD79b) are essential components of BCR that are indispensable for its functionality, signal initiation, and signal transduction. CD79a/CD79b-mediated BCR signaling is required for the survival of normal as well as malignant B cells via a wide signaling network. Recent studies identified the great complexity of this signaling network and revealed the emerging role of CD79a/CD79b in signal integration. In this review, we have focused on functional features of CD79a/CD79b, summarized signaling consequences of CD79a/CD79b post-translational modifications, and highlighted specifics of CD79a/CD79b interactions within BCR and related signaling cascades. We have reviewed the complex role of CD79a/CD79b in multiple aspects of normal B cell biology and how is the normal BCR signaling affected by lymphoid neoplasms associated CD79A/CD79B mutations. We have also summarized important unresolved questions and highlighted issues that remain to be explored for better understanding of CD79a/CD79b-mediated signal transduction and the eventual identification of additional therapeutically targetable BCR signaling vulnerabilities. Full article

(This article belongs to the Special Issue New Advances in B-cell Lymphoma Biology)

► Show Figures

Figure 1

Journal Menu

Journal Browser

New Advances in B-cell Lymphoma Biology

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (2 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI